nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Clinical use of ipilimumab for metastatic melanoma in Spain: towards a more consistent approach
|
Martín-Algarra, S. |
|
2016 |
18 |
10 |
p. 1044-1050 |
artikel |
2 |
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse
|
Orlandi, A. |
|
2015 |
18 |
10 |
p. 988-995 |
artikel |
3 |
Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics
|
Moreno, L. |
|
2015 |
18 |
10 |
p. 981-987 |
artikel |
4 |
Influence of different treatment techniques and clinical factors over the intrafraction variation on lung stereotactic body radiotherapy
|
Rico, M. |
|
2016 |
18 |
10 |
p. 1011-1018 |
artikel |
5 |
Ki-67 is a prognostic marker for hormone receptor positive tumors
|
Pérez-López, M. E. |
|
2015 |
18 |
10 |
p. 996-1002 |
artikel |
6 |
Long-term visual outcomes in intraocular retinoblastoma with eye preservation
|
Batra, A. |
|
2016 |
18 |
10 |
p. 1034-1038 |
artikel |
7 |
Pro-gastrin-releasing peptide and neuron-specific enolase: useful predictors of response to chemotherapy and survival in patients with small cell lung cancer
|
Huang, Z. |
|
2016 |
18 |
10 |
p. 1019-1025 |
artikel |
8 |
Role of taxanes in advanced prostate cancer
|
Cassinello, J. |
|
2016 |
18 |
10 |
p. 972-980 |
artikel |
9 |
Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer
|
Nicoś, M. |
|
2016 |
18 |
10 |
p. 1039-1043 |
artikel |
10 |
Signaling and molecular basis of bone marrow niche angiogenesis in leukemia
|
Shirzad, R. |
|
2015 |
18 |
10 |
p. 957-971 |
artikel |
11 |
Stereotactic body radiation therapy and intensity modulated radiation therapy induce different plasmatic cytokine changes in non-small cell lung cancer patients: a pilot study
|
Trovo, M. |
|
2015 |
18 |
10 |
p. 1003-1010 |
artikel |
12 |
The number of risk factors is the strongest predictor of prostate cancer mortality: multi-institutional outcomes of an extreme-risk prostate cancer cohort
|
Gomez-Iturriaga, A. |
|
2016 |
18 |
10 |
p. 1026-1033 |
artikel |